Metraipolis › archive › dc_1b2251ae4e71
6-MBPB — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/6-MBPB
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-06T18:53:33.328Z
- SHA-256 of the archived text
82a3dba59324ac233bd9c7462b604bf0239072d497c5924b24edfc993321a9a7- Stable URL of this page
https://metraipolis.com/documento/dc_1b2251ae4e71
How to cite
6-MBPB — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/6-MBPB (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_1b2251ae4e71 (Metraipolis archive dc_1b2251ae4e71, sha256 82a3dba59324ac233bd9c7462b604bf0239072d497c5924b24edfc993321a9a7)
BibTeX
@misc{dc1b2251ae4e71,
title = {6-MBPB — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/6-MBPB},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_1b2251ae4e71; sha256 82a3dba59324ac233bd9c7462b604bf0239072d497c5924b24edfc993321a9a7},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/6-MBPB. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
6-MBPB, also known as 6-(2-methylaminobutyl)benzofuran (6-MABB), is a monoamine releasing agent (MRA) and entactogen-like drug of the amphetamine, phenylisobutylamine, and benzofuran families. It is a positional isomer of 5-MBPB (5-MABB). The drug appears to act as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). The EC50Tooltip half-maximal effective concentration values for induction of monoamine release in rat brain synaptosomes have been reported for the individual enantiomers of 6-MBPB. In the case of (S)-6-MBPB, they were 54 nM for serotonin, 77 nM for norepinephrine, and 41 nM for dopamine, whereas for (R)-6-MBPB, they were 172 nM for serotonin, 227 nM for norepinephrine, and inactive for dopamine. Hence, (S)-6-MBPB is an SNDRA, whereas (R)-MBPB is a serotonin–norepinephrine releasing agent (SNRA). The enantiomers showed a mixed profile of acting as full versus partial releasers. Unlike 5-MAPB, it is a relatively weak serotonin 5-HT1B receptor agonist. 6-MBPB partially substituted for MDMA in animal drug discrimination tests at lower doses and fully substituted for MDMA at the highest dose, suggesting that it has entactogen-like effects. Along with 5-MBPB, 6-MBPB was patented by Matthew Baggott and Tactogen in 2021. It was first described in the scientific literature by 2022. 6-MBPB, along with other drugs like 5-MBPB, is being investigated as a novel MDMA-like drug for potential therapeutic purposes in medicine. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «6-MBPB» — https://en.wikipedia.org/wiki/6-MBPB Wikidata Q132132582: «pharmaceutical compound» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q132132582 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/6-MBPB?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1339382465, consultata il 2026-11-06T18:49:58.307Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: abf16c07daa17460d1f70fa55342246a423fc59a019b98c9527209aa37a90e52